First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
about
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals.Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER.The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.The roles of the nuclear pore complex in cellular dysfunction, aging and disease.Role of Host Genes in Influenza Virus Replication.What's new in treatment of pancreatic cancer: a patent review (2010-2017).Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear exportPhase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.Nuclear Export Inhibition for Pancreatic Cancer Therapy.Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity.Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumorsRedox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatmentPhase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphomaAnti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
P2860
Q33434141-371EF9C7-B23F-419B-97A6-A6AED3A01C6EQ33442836-100F716D-4147-4124-80C4-C39FF31D8525Q37302065-014836C3-40C2-405B-8FA2-DB55D5A84BF9Q37510564-10D6FD61-F93F-4D2C-9BAA-FD1AD55A3A77Q37694722-77A03A4F-AFDA-43E1-9E7C-11AC19C39919Q37702556-3DDA2D73-7249-4FF5-A2AE-9EB9DDFC6F6FQ37712229-742397E1-5404-4B94-A3B1-D66FB4CCA330Q38687169-65338388-0ABB-4112-B62E-30B1AD3553E4Q38718460-BC9F8D9E-DDF7-4DE3-B87F-6F12096C85CDQ38881093-50D33D47-2025-43E5-ADDF-0ED3A127F8AAQ39135290-375EE816-1A1D-4BDA-925A-A37B2CD1528AQ39308124-5DDB637B-210B-4B23-A52F-1D7ACCACD228Q39393272-0492D540-EA79-416A-ABEE-0B0FE3B01460Q39406815-1D3736FF-3ECA-4DE5-AFB9-5469D1FBD089Q40578878-18D752A2-FA58-476B-ABD9-F78D67A5E79EQ41087485-601A04AD-DC82-48B0-905A-0976284B8239Q41412563-361E718A-20F4-4D05-9B0D-9BCFCBF98B52Q41550563-866D721D-4392-4FD8-A503-058A602D58AAQ47113773-8790F886-18AF-44B7-A2C4-001E49A3CD94Q47562624-9163AF00-7EA1-401C-AE14-568AA46552EDQ47748570-AB09EEB5-5377-4FDE-9316-33E64DF6FDF9Q48743003-F7941323-B87B-4872-964A-A441C6DEF71FQ49188547-C58D62FA-AA06-4FF9-A672-702A6A0B43B5Q49299822-F4DF543D-09BC-44C7-B197-434F1D3DB57DQ51157837-16E4DFA1-797E-4641-AB8E-CCD3150BB058Q52682469-5A96D48F-D685-4698-A975-581041F65990Q55040338-959FAC9F-E4EC-4519-A81A-E44DAA3C2ABDQ55086372-16739722-DC30-4EC5-8D8D-62A2AD654C26Q55386332-C1D25493-B648-465C-B02C-6984866F68AEQ57099831-35522089-D790-48E1-B6F6-5A6C710917B5Q58699598-EA73C22D-482F-4616-9B65-8F2AACCD3D98Q58707427-1A2D477C-116C-4E1E-B112-DEC3B194505FQ58774746-C77E64A9-F4E6-47ED-A782-81F47DC022E7
P2860
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@ast
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@en
type
label
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@ast
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@en
prefLabel
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@ast
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@en
P2093
P2860
P50
P356
P1476
First-in-Class, First-in-Human ...... nts With Advanced Solid Tumors
@en
P2093
Albiruni R Abdul Razak
Anthony F Shields
Dilara McCauley
Jean R Saint-Martin
John F Gerecitano
Lee-Anne Stayner
Mansoor R Mirza
Michael Kauffman
Nashat Y Gabrail
Richard Kim
P2860
P304
P356
10.1200/JCO.2015.65.3949
P407
P577
2016-02-29T00:00:00Z